 CAMBRIDGE, Mass.--BUSINESS WIRE--Axcella Nasdaq: AXLA, a clinical-stage biotechnology company pioneering a new approach to treat complex diseases and improve health using endogenous metabolic modulator EMM compositions, today announced that positive data from the companys AXA1665-002 clinical study were presented last night at the Digestive Disease Week DDW 2021 Annual Meeting by Dr. Arun Sanyal, Professor in the Virginia Commonwealth University VCU Department of Internal Medicine an 